<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423810</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00141337</org_study_id>
    <secondary_id>UL1TR002366</secondary_id>
    <nct_id>NCT03423810</nct_id>
  </id_info>
  <brief_title>Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients</brief_title>
  <official_title>Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like
      protein) in the urine that is changed after treatment of hydralazine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">May 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in polycystin-1 (PC1)</measure>
    <time_frame>Change from Baseline to Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mucin-like protocadherin (MUPCDH)</measure>
    <time_frame>Change from Baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating methylated RASAL1 levels</measure>
    <time_frame>Change from Baseline to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Polycystic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1: Hydralazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydralazine</intervention_name>
    <description>Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.</description>
    <arm_group_label>Group 1: Hydralazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of ADPKD

          -  estimated glomerular filtration rate (eGFR) &gt; 60 ml/min/1.73m^2

        Exclusion Criteria:

          -  History of systemic lupus erythematous or other rheumatologic disorder

          -  Baseline anti-nuclear antibody (ANA) &gt;1:80 for females and &gt;1:40 for males

          -  Blood pressure &lt; 120/80 without anti-hypertensive

          -  Angina pectoris or myocardial infarction in the last 6 months

          -  Liver disease

          -  Allergy to hydralazine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerri McGreal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Griffin, RN</last_name>
    <phone>913-588-7691</phone>
    <email>dgriffin3@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydralazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

